Nivolumab: Difference between revisions
From IDWiki
Content deleted Content added
Created page with "* Immune checkpoint inhibitor targeting PD-1 * Indicated for melanoma, NSCLC, SCLC, RCC, Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma * Not particularly immunosuppressive * May increase risk of routine bacterial infections (including C. difficile), fungal infections (aspergillosis, pneumocystis, candidemia), viral infections (V..." |
No edit summary |
||
| Line 1: | Line 1: | ||
== Background == |
|||
* Immune checkpoint inhibitor targeting PD-1 |
|||
* IgG4 human monoclonal antibody that binds PD-1 receptor on T cells, thus blocking it from interacting with PD-L1 and PD-L2 |
|||
* Indicated for [[melanoma]], [[NSCLC]], [[SCLC]], [[RCC]], [[Hodgkin lymphoma]], head and neck squamous cell carcinoma, urothelial carcinoma, [[colorectal cancer]], [[hepatocellular carcinoma]], and esophageal squamous cell carcinoma |
* Indicated for [[melanoma]], [[NSCLC]], [[SCLC]], [[RCC]], [[Hodgkin lymphoma]], head and neck squamous cell carcinoma, urothelial carcinoma, [[colorectal cancer]], [[hepatocellular carcinoma]], and esophageal squamous cell carcinoma |
||
* Not particularly immunosuppressive |
|||
=== Pharmacokinetics === |
|||
| ⚫ | |||
* Half-life 27 days |
|||
== Safety == |
|||
| ⚫ | |||
* Rash is common, generally presenting early |
|||
* Diarrhea as well, can be severe, as well as nausea/vomiting |
|||
* Fatigue quite common, affecting about a half of patients |
|||
* Electrolyte abnormalities |
|||
* Immune-mediated endocrinopathies that can include hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency, diabetes mellitus |
|||
* Cases of pneumonitis and interstitial lung disease, median onset 15 weeks |
|||
== Further Reading == |
|||
* https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/44416 |
|||
[[Category:Immune checkpoint inhibitors]] |
[[Category:Immune checkpoint inhibitors]] |
||
Latest revision as of 16:23, 27 February 2026
Background
- IgG4 human monoclonal antibody that binds PD-1 receptor on T cells, thus blocking it from interacting with PD-L1 and PD-L2
- Indicated for melanoma, NSCLC, SCLC, RCC, Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma
Pharmacokinetics
- Half-life 27 days
Safety
- Not particularly immunosuppressive; may increase risk of routine bacterial infections (including Clostridioides difficile), fungal infections (aspergillosis, Pneumocystis, candidemia), viral infections (VZV, CMV, EBV); case reports of CMV colitis
- Rash is common, generally presenting early
- Diarrhea as well, can be severe, as well as nausea/vomiting
- Fatigue quite common, affecting about a half of patients
- Electrolyte abnormalities
- Immune-mediated endocrinopathies that can include hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency, diabetes mellitus
- Cases of pneumonitis and interstitial lung disease, median onset 15 weeks
